SALT LAKE CITY - LifeVantage (NASDAQ:LFVN) Corporation (NASDAQ:LFVN), a company focused on health and wellness products, has declared a quarterly cash dividend of $0.04 per share. The dividend is payable on December 16, 2024, to shareholders of record as of December 2, 2024.
The announcement was made today, and it marks a continuation of the company's commitment to providing returns to its shareholders. LifeVantage, known for its range of products that support health at the cellular level, has been a player in the nutrigenomics field—a science studying the effect of nutrition and natural compounds on gene expression.
LifeVantage's product portfolio includes the Protandim® family, TrueScience® Liquid Collagen, and a variety of other wellness products aimed at improving health. These are sold through a network of independent consultants who also have the opportunity to build their own sales businesses with the company's support.
The company, founded in 2003 and headquartered in Lehi, Utah, has emphasized that the declaration of this dividend does not guarantee future dividend payments. The timing and amount of future dividends may change based on a range of factors, including business performance and economic conditions.
Investors are advised to consider the forward-looking statements with caution, as they involve risks and uncertainties, including the potential impact of COVID-19 on the business and the global economic climate. These uncertainties are detailed in the company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
The announcement of the dividend is based on a press release statement from LifeVantage Corporation.
In other recent news, LifeVantage Corporation has made significant strides in its research and development efforts. The company concluded a 12-week clinical trial focused on evaluating the efficacy of its GLP-1 system for weight management. The trial, which involved 60 participants, assessed the impact of the two-product system on weight management and overall well-being. The findings from this trial will be disclosed at the upcoming Market Connect event in Kansas City.
LifeVantage's recent in vitro study also reported a significant boost in GLP-1 hormone production, a key factor in weight management and glucose regulation. The study showcased the synergistic effects of a new two-product system designed to enhance GLP-1 hormone production on specialized L-cells in the colon.
Despite a nearly 10% decrease in total revenues, LifeVantage managed to preserve its profitability, reporting a 9.8% adjusted EBITDA margin, a 90 basis point improvement year-over-year. The company has also demonstrated its commitment to creating shareholder value by announcing a share repurchase and a quarterly cash dividend of $0.04 per share. For the fiscal year 2025, the company projects its revenue to fall between $200 million and $210 million, with adjusted non-GAAP EBITDA expected to range between $18 million and $21 million.
InvestingPro Insights
LifeVantage Corporation's recent dividend announcement aligns with its strong financial position and commitment to shareholder returns. According to InvestingPro data, the company's dividend yield stands at 1.19%, with a notable dividend growth of 14.29% over the last twelve months. This increase in dividend payout is particularly significant given the company's impressive gross profit margin of 79.3%, which provides ample room for such shareholder-friendly actions.
InvestingPro Tips highlight that LifeVantage holds more cash than debt on its balance sheet, indicating a solid financial foundation. This conservative financial approach supports the company's ability to maintain and potentially increase its dividend payments in the future. Additionally, the company's management has been aggressively buying back shares, further demonstrating their confidence in LifeVantage's value proposition and commitment to enhancing shareholder returns.
Despite a slight revenue decline of 6.2% over the last twelve months, LifeVantage has maintained profitability, with analysts predicting continued profitability for the current year. The company's ability to generate profits even in challenging times speaks to the resilience of its business model and the effectiveness of its product portfolio in the health and wellness sector.
For investors seeking more comprehensive insights, InvestingPro offers an additional 14 tips for LifeVantage, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.